Wednesday, July 8, 2026

pharma · Narcolepsy and Idiopathic Hypersomnia · Narcolepsy Type 1 · CNTA

Centessa Pharmaceuticals

Centessa Pharmaceuticals is a pharma organization headquartered in Cheshire, GB. It trades on NYSE under ticker CNTA. Primary therapeutic focus areas include Narcolepsy and Idiopathic Hypersomnia, Narcolepsy Type 1, Adva

1 Ashley Road, Cheshire, WA14 2DT, United Kingdom, GB HQ
2021 Founded
142 Employees
Public company Type
CNTA · NYSE Ticker
Company details
Status
Public
HQ
1 Ashley Road, Cheshire, WA14 2DT, United Kingdom, GB
Founded
2021
Employees
142
Programs
15
Drugs
11
Patents
7
Clinical program

ORX750

Phase 2 · small molecule · Narcolepsy Type 1

ORX750 for Narcolepsy Type 1 is a Phase 2 program (small_molecule) at Centessa Pharmaceuticals plc with 2 ClinicalTrials.gov record(s).

Internal code ORX750-0201

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Centessa Pharmaceuticals plc
Phase
Phase 2
Modality
small_molecule
Indication
Narcolepsy Type 1
Status
active
Trials
2

Clinical trials